Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Find an upcoming class
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / NEWS & MEDIA / Zoetis Launches Clavamox® Chewable for Dogs and Cats
Trusted antibiotic is now available in a highly palatable,1 easy-to-administer chewable tablet
PARSIPPANY, N.J. — Aug. 14, 2017 — Zoetis today announced the commercial launch of Clavamox® Chewable (amoxicillin and clavulanate potassium tablets), which is effective in treating skin infections in dogs and cats, periodontal infections in dogs and urinary tract infections in cats. This product was approved by the U.S. Food and Drug Administration on May 24, 2017. As a highly palatable,1 easy-to-administer formulation, Clavamox Chewable features the same broad-spectrum efficacy, dosing, and strengths as the original film-coated Clavamox Tablet that has been used by veterinarians for decades. Clavamox Chewable is now available to all veterinarians in the United States.
“Clavamox Chewable is a prime example of how we focus our innovation at Zoetis on addressing the challenges of our veterinary customers and improving the lives of the animals in their care,” said J. Michael McFarland, DVM, DAVBP, Executive Director, Companion Animal Marketing. “This innovation was made possible by our customers’ loyal support of the Clavamox brand over more than 30 years.”
This new chewable formulation combines the reliability and effectiveness of Clavamox with the same pork-liver-flavored chewable base used in Rimadyl® (carprofen) Chewable. The palatability of Clavamox Chewable was established in a clinical trial that studied client-owned dogs at VCA veterinary hospitals across the U.S. and was conducted to a protocol approved by FDA’s Center for Veterinary Medicine. A total of 1,567 doses were administered to 112 dogs, resulting in an 83 percent overall voluntary acceptance rate for Clavamox Chewable when offered from an empty bowl or owner’s hand.*,1 This clinical trial is an example of a successful collaboration between Zoetis, the world’s largest animal health company, and a global veterinary hospital corporation, VCA.
Clavamox Chewable is available in four strengths (62.5 mg, 125 mg, 250 mg and 375 mg) and is packaged in boxes of 100 tablets. Veterinarians can continue to purchase Clavamox Drops and original film-coated Clavamox Tablet formulations.
For more information about Clavamox Chewable and full Prescribing Information, visit clavamoxchewable.com.
IMPORTANT SAFETY INFORMATION:People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Clavamox Chewable. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins.
About ZoetisZoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
For Further information contact:Colleen White Zoetis 973-822-7203 firstname.lastname@example.org
Lindsey GoodmanArcher Malmo706email@example.com
References:*One hundred twelve (112) dogs with 1567 total tablet administrations successfully completed the study and were included in the data summary. Of the 1567 doses administered, CLAVAMOX CHEWABLE tablets were fully consumed within five minutes 82.51% of the time. Tablets were fully consumed within two minutes 81.17% of the time. The percent acceptance was consistent over 14 doses (seven days). For the first dose given, 93/112 dogs (83.04%) consumed the entire dose within two minutes. For the last (14th) dose, 89/111 dogs (80.18%) consumed the entire dose within two minutes, indicating that tablet acceptability continued over time without development of aversion to the tablet(s).
1Data on file. CLAVAMOX CHEWABLE Tablets Palatability Study in Client-Owned Dogs. Study No. A163C-US-13-170, Zoetis Inc.
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2019 Zoetis Services LLC. All rights reserved.